A Case of Pancreatitis with a Similar Course to Autoimmune Pancreatitis Occurring After Pembrolizumab Therapy in a Patient with Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Case of Pancreatitis with a Similar Course to Autoimmune Pancreatitis Occurring After Pembrolizumab Therapy in a Patient with Non-small Cell Lung Cancer

Published:2018-10-20 Issue:5 Volume:58 Page:344-348
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Kasahara Chinatsu¹,Wada Yukiko²,Matsuo Masaki¹,Machida Kazuhiko¹,Matsushita Akihiro¹,Ito Hiroshi¹

Affiliation:

1. Department of Respiratory Medicine, Japan Organization of Occupational Health and Safety (JOHAS), Chubu Rosai Hospital

2. Department of Palliative Medicine, Shizuoka Cancer Center

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/58/5/58_344/_pdf

Reference8 articles.

1. 1. Hu YB, Zhang Q, Li HJ, Michot JM, Liu HB, Zhan P, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017; 6(Suppl 1): S8-S20.

2. 2. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375: 1823-1833.

3. 3. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387: 1540-1550.

4. Recent Topics in Management of Autoimmune Pancreatitis

5. 5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372: 2521-2532.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Steroid Therapy and Steroid Response in Autoimmune Pancreatitis;International Journal of Molecular Sciences;2019-12-30

2. Pembrolizumab;Reactions Weekly;2018-12